Allogene Therapeutics shares rise 1.92% premarket after reporting better-than-expected Q2 earnings.

Allogene Therapeutics, Inc. rose 1.92% in premarket trading. The company reported a loss of $50.9 million in its second quarter, but the results exceeded Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss of 28 cents per share, while the company reported a loss of 23 cents per share.